Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)

Tadakazu Hisamatsu,Shingo Kato,Reiko Kunisaki,Minoru Matsuura,Masakazu Nagahori,Satoshi Motoya,Motohiro Esaki,Norimasa Fukata,Satoko Inoue,Takeshi Sugaya,Hirotake Sakuraba,Fumihito Hirai,Kenji Watanabe,Takanori Kanai,Makoto Naganuma,Hiroshi Nakase,Yasuo Suzuki,Mamoru Watanabe,Toshifumi Hibi,Masanori Nojima,Takayuki Matsumoto

Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)

2019

Background The risk:benefit ratio of concomitant use of thiopurines with scheduled adalimumab (ADA) maintenance therapy for Crohn’s disease is controversial. The aim of this study is to identify the influence of withdrawal of thiopurines in patients in remission with combination therapy in an open-label, randomised, controlled trial (DIAMOND2; UMIN000009596).

Keywords:

Clinical trial
General surgery
Diabetes mellitus
Internal medicine
Adalimumab
Crohn's disease
Medicine
Clinical endpoint
Concomitant
Randomized controlled trial
Trough level
Maintenance therapy
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations